FM
Fidelity Management & Research Company
Boston, Massachusetts, United StatesFounded 1946
Biotech & Life SciencesMobility & TransportationAILogistics & Supply ChainHardware & SemiconductorsHealthcareDefense & Space
Fidelity Management & Research Company's venture capital strategy focuses on investing in mid-to-late stage, rapidly growing category disruptors with durable competitive advantages and experienced management teams. Their investments primarily target the technology, media, and telecommunications sectors globally, with a strong emphasis on North America.
Deal activity increased 62% year-over-year (13 deals in the last 12 months). Average disclosed round size is $447.2M (across 56 rounds with reported amounts).
Portfolio
58
Fund Size
—
Top Stage
Growth
Last 12 Mo
13
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
58 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Zipline | Series H | $800M | Mar 2026 |
 SHINE Technologies | Growth | $240M | Feb 2026 |
 Skyryse | Series C | $300M | Feb 2026 |
| Skyryse | Series C | — | Feb 2026 |
 Zipline International Inc. | Growth | $600M | Jan 2026 |
| Zipline | Growth | $600M | Jan 2026 |
 Lyte, Inc. | Unknown | $107M | Jan 2026 |
 Crusoe | Series E | $1.4B | Oct 2025 |
 Nscale | Series B | $936M | Sep 2025 |
 Empower Semiconductor | Series D | $140M | Sep 2025 |
 Galvanize Therapeutics | Series C | $100M | Sep 2025 |
 Nuro | Series E | $203M | Aug 2025 |
 Applied Intuition | Series F | $600M | Jun 2025 |
 Anthropic | Series E | $3.5B | Mar 2025 |
 Oura | Series D | $200M | Dec 2024 |
 Tenstorrent | Series D | $693M | Dec 2024 |
 Lightmatter | Series D | $400M | Oct 2024 |
 Triveni Bio Inc. | Series B | $115M | Oct 2024 |
 Anduril | Growth | $1.5B | Aug 2024 |
 Insightec | Growth | $150M | Jun 2024 |
 CoreWeave | Series C | $1.1B | May 2024 |
| CoreWeave | Unknown | — | Dec 2023 |
 Databricks | Growth | $500M | Nov 2023 |
 Generate:Biomedicines | Series C | $273M | Sep 2023 |
| RRapport Therapeutics | Series B | $150M | Aug 2023 |
Page 1 of 3
Top Co-Investors
Baillie Gifford15 shared
Tiger Global Management10 shared
T. Rowe Price Associates, Inc.9 shared
General Catalyst9 shared
T. Rowe Price6 shared
Nvidia5 shared
Valor Equity Partners5 shared
Atreides Management5 shared
Qatar Investment Authority5 shared
GV (Google Ventures)5 shared
Fidelity Investments5 shared
BlackRock4 shared
Coatue Management4 shared
Durable Capital Partners4 shared
OrbiMed4 shared
Andreessen Horowitz4 shared
Jane Street Capital4 shared
Salesforce3 shared
Gilmartin Capital3 shared
Sofinnova Partners3 shared
Last updated: 12 April 2026